Immix Biopharma Inc (IMMX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$7.20-9.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · IMMX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -68.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
IMMX — debt issuance
Dated 2026-09-30
Other Events. On September 29, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, pursuant to which the Company agreed to issue and sell, in an underwritten offering (the “Offering”), an aggregate of 11,363,637 shares of its common stock, par value $0.0001 per share (the “Shares”) at a public offering price of $11.00 per Share. The Underwriting Agreement contains customary…
Why it matters: The trial's final results will test whether the strong interim response holds. A BLA filing would mark the next step toward review.
Watch forBy mid-2027, the company reports final NEXICART-2 results and submits a BLA. Response rates are close to the interim 89% CR rate.
Also watch forFinal results fall well below the interim 89% CR rate, or the planned BLA submission slips past mid-2027.
Why it matters: The company says these patients may later reach complete response. Their results will test that claim.
Supportive ifThe next trial update says whether all four pending MRD-negative patients reach complete response within one year of treatment.
Worry ifOne or more of the four patients fails to reach complete response within one year of treatment.
Why it matters: The company raised $125 million in September, but it remains loss-making. Cash use will show how long funds may support trial work.
Worry ifThe Nov. 6 update shows cash use rising from the reported $9.8 million used in operations in 2026-Q1, or cuts the stated runway into mid-2028.
Less concerning ifThe Nov. 6 update shows cash use at or below $9.8 million for the quarter, with runway still stated to reach mid-2028.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$292 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $736 loss on $10,000 · 7.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,024 loss on $10,000 · 50.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.